Introduction {#Sec1}
============

Recent evidence suggests low-flow extracorporeal CO2 removal (ECCO2-R) systems as safe and promising adjunctive therapy to avoid endotracheal intubation and the related negative consequences in subjects with severe hypercapnic respiratory failure \[[@CR1]\]. in high-flow extracorporeal membrane oxygenation systems heterogeneous coagulation disorders are a well-known complication. However, to date there is little evidence for the influence of pump-driven low-flow veno-venous ECCO2-R on the coagulation system.

Objectives {#Sec2}
==========

This study is a retrospective analysis of four subjects developing coagulation disorders with bleeding complications while undergoing ECCO2-R.

Methods {#Sec3}
=======

Four subjects treated with a pump-driven veno-venous ECCO2-R (system: iLA Activve®; membrane ventilator: Minilung®; Novalung GmbH, Talheim, Germany) for severe hypercapnic respiratory failure due to acute exacerbation of COPD were included in this study. Unfractionated heparin was used for anticoagulation with a target aPTT of 45-55 sec. Coagulation parameters i.e. hemoglobin, platelets, fibrinogen, antithrombin and D-DIMER were retrieved from the charts at treatment initiation and during the time range starting 72 hours before and ending at the clinical onset of the bleeding complication.

Results {#Sec4}
=======

Mean application time of ECCO2-R was 196.5 h ( ± 77.4) with an average blood flow of 1.1 l/min ( ± 0.2). Bleeding events consisted of two pulmonary bleedings, one large soft tissue hematoma and one hemothorax. Coagulation parameters are depicted below in Table [1](#Tab1){ref-type="table"}. ECCO2-R was removed in all subjects after onset of the bleeding complication resulting in stabilization of the coagulation state.Table 1*Coagulation parameters.*baseline\*-72h-48h-24hday of bleeding**hemoglobin (G/l)**114.5 ( ± 24.3)97.8 ( ± 11.8)88.8 ( ± 16.9)79 ( ± 14.5)81.8 ( ± 14.1)**thrombocytes (G/l)**195.5 ( ± 125.5)193.3 ( ± 136.0)171 ( ± 122.5)141.8 ( ± 122.1)125.5 ( ± 100.2)**fibrinogen (mg/dl)**370 ( ± 97.4)358.8 ( ± 133.9)343.5 ( ± 136.3)255.5 ( ± 136.2)235.5 ( ± 142.9)**AT III (%)**101 ( ± 20.9)86 ( ± 25.7)80.5 ( ± 21.6)69.5 ( ± 23.7)74 ( ± 14.5)**D-DIMER (µg/l)**1170 ( ± 435.4)5079 ( ± 6597)7569 ( ± 11340)11048 ( ± 16140)12709 ( ± 15453)**PT (%)**90.8 ( ± 18.7)91 ( ± 19.8)86.8 ( ± 18.8)81.8 ( ± 16.9)82.5 ( ± 24.8)**aPTT (sec)**38.8 ( ± 12.0)39.8 ( ± 10.4)46.8 ( ± 11.3)49.5 ( ± 15.1)36.8 ( ± 7.7)**Heparin (IU/kg/day)**0207.8 ( ± 80.5)259.7 ( ± 84.3)150.1 ( ± 115.7)78.33 ( ± 97.1)Results are presented as mean ( ± SD).\*baseline refers to the last value before application of ECCO2-R

Conclusions {#Sec5}
===========

Despite adequate anticoagulation subjects undergoing pump-driven veno-venous ECCO2-R developed coagulation disorders similar to disseminated intravascular coagulation with concomitant bleeding complications. the underlying mechanism remains to be clarified.
